A Phase II Double-blind, Randomized, Prospective, Placebo Controlled Study of NanO2 TM Combined with Radiation and Temozolomide in Patients with Newly-Diagnosed Glioblastoma Multiforme: RESTORE
Details
A phase 2 double-blind, RandomizEd, prospective, placebo
controlled STudy of NanO2TM combined with Radiation and temozolomide in patients with newly-diagnosed glioblastoma multiformE: RESTORE
Eligibility
You can join if...
Inclusion Criteria:
Histologically confirmed, newly diagnosed primary or secondary glioblastoma multiforme
Treatment plan includes 60 Gy of focal radiation administered in 30 fractions, concurrently
with temozolomide chemotherapy.
Life expectancy of at least 3 months
Exclusion Criteria:
Recurrent Glioblastoma
Prior treatment for glioblastoma apart from surgical resection.
Presence of multi-focal glioblastoma disease that cannot be encompassed into a radiation
treatment field that would be safely treated to the prescribed radiation dose